Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK
Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the an...
Gespeichert in:
Veröffentlicht in: | Theranostics 2020-01, Vol.10 (17), p.7710-7729 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 7729 |
---|---|
container_issue | 17 |
container_start_page | 7710 |
container_title | Theranostics |
container_volume | 10 |
creator | Hu, Xiong-Ke Rao, Shan-Shan Tan, Yi-Juan Yin, Hao Luo, Ming-Jie Wang, Zhen-Xing Zhou, Jin-Hua Hong, Chun-Gu Luo, Zhong-Wei Du, Wei Wu, Ben Yan, Zi-Qi He, Ze-Hui Liu, Zheng-Zhao Cao, Jia Wang, Yang Situ, Wei-Yi Liu, Hao-Ming Huang, Jie Wang, Yi-Yi Xia, Kun Qian, Yu-Xuan Zhang, Yan Yue, Tao Liu, Yi-Wei Zhang, Hong-Qi Tang, Si-Yuan Chen, Chun-Yuan Xie, Hui |
description | Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects.
A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays
were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis.
The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK).
Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy. |
doi_str_mv | 10.7150/thno.45858 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7359101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2598248418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</originalsourceid><addsrcrecordid>eNpVUV1r3iAYldGxlne96Q8YQu8K6TRRk9wMSru2Y4WOtfdiokksiU-q5h3vv9pPnOkXnTzw-ODxnKMHoSNKTkvKydc4ODhlvOLVB3RAq6LKSsHI3rv9PjoM4YGkxUhe0_oT2i9yUXFC-QH6e-mXNkIwWQsqGo3PXB-ihwkHO26Nx9YNtrExYAjRQFC-hUnh3sOfOGDlNJ5MVCGVDXhrFZ7TXYjW9fj37V2mzWycNi5iNcOcdBIqDh6WfkjdYDVG41W04DB0uB-XNll5omxgtGHCze7VwUr56-LnZ_SxU2Mwhy99g-4vv9-fX2c3t1c_zs9uspYRETOqa22I4FQ1otM144asoyh0QQkXrC1F-g7CWcVYU5dMEMHKUnd5UYsVtkHfnmnnpZmMbtMTvBrl7O2k_E6CsvL_E2cH2cNWlgWvKaGJ4PiFwMPjYkKUD7B4lyzLnNdVnoRTQht08oxqPYTgTfemQIlc85VrvvIp3wT-8t7TG_Q1zeIfJAWlpg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598248418</pqid></control><display><type>article</type><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</creator><creatorcontrib>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</creatorcontrib><description>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects.
A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays
were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis.
The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK).
Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.45858</identifier><identifier>PMID: 32685015</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Adolescent ; Animals ; Apoptosis ; Apoptosis - drug effects ; Aqueous solutions ; Bone cancer ; Bone Neoplasms - drug therapy ; Bone Neoplasms - pathology ; Cancer therapies ; Carbon ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Chemotherapy ; Cisplatin - administration & dosage ; Dehydrogenases ; Efficiency ; Female ; Fructose - chemistry ; Glucose ; Humans ; Infant ; Infant, Newborn ; Injections, Intravenous ; Kinases ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - secondary ; Male ; Metabolism ; Metal Nanoparticles - administration & dosage ; Metal Nanoparticles - chemistry ; Metastasis ; Mice ; Mitochondria - drug effects ; Mitochondria - metabolism ; Osteosarcoma - drug therapy ; Osteosarcoma - secondary ; Oxidation-Reduction - drug effects ; Pancreatic cancer ; Pharmacokinetics ; Primary Cell Culture ; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists & inhibitors ; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism ; Reactive oxygen species ; Reactive Oxygen Species - metabolism ; Renal Elimination ; Research Paper ; Sarcoma ; Signal Transduction - drug effects ; Silver - administration & dosage ; Silver - pharmacokinetics ; Silver - urine ; Tissue Distribution ; Tumors ; Warburg Effect, Oncologic - drug effects ; Xenograft Model Antitumor Assays ; Young Adult</subject><ispartof>Theranostics, 2020-01, Vol.10 (17), p.7710-7729</ispartof><rights>The author(s).</rights><rights>2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359101/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359101/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32685015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Xiong-Ke</creatorcontrib><creatorcontrib>Rao, Shan-Shan</creatorcontrib><creatorcontrib>Tan, Yi-Juan</creatorcontrib><creatorcontrib>Yin, Hao</creatorcontrib><creatorcontrib>Luo, Ming-Jie</creatorcontrib><creatorcontrib>Wang, Zhen-Xing</creatorcontrib><creatorcontrib>Zhou, Jin-Hua</creatorcontrib><creatorcontrib>Hong, Chun-Gu</creatorcontrib><creatorcontrib>Luo, Zhong-Wei</creatorcontrib><creatorcontrib>Du, Wei</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Yan, Zi-Qi</creatorcontrib><creatorcontrib>He, Ze-Hui</creatorcontrib><creatorcontrib>Liu, Zheng-Zhao</creatorcontrib><creatorcontrib>Cao, Jia</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Situ, Wei-Yi</creatorcontrib><creatorcontrib>Liu, Hao-Ming</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Yi-Yi</creatorcontrib><creatorcontrib>Xia, Kun</creatorcontrib><creatorcontrib>Qian, Yu-Xuan</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Yue, Tao</creatorcontrib><creatorcontrib>Liu, Yi-Wei</creatorcontrib><creatorcontrib>Zhang, Hong-Qi</creatorcontrib><creatorcontrib>Tang, Si-Yuan</creatorcontrib><creatorcontrib>Chen, Chun-Yuan</creatorcontrib><creatorcontrib>Xie, Hui</creatorcontrib><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects.
A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays
were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis.
The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK).
Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</description><subject>Adolescent</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Aqueous solutions</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Carbon</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Dehydrogenases</subject><subject>Efficiency</subject><subject>Female</subject><subject>Fructose - chemistry</subject><subject>Glucose</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Injections, Intravenous</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - secondary</subject><subject>Male</subject><subject>Metabolism</subject><subject>Metal Nanoparticles - administration & dosage</subject><subject>Metal Nanoparticles - chemistry</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - secondary</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Pancreatic cancer</subject><subject>Pharmacokinetics</subject><subject>Primary Cell Culture</subject><subject>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists & inhibitors</subject><subject>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Renal Elimination</subject><subject>Research Paper</subject><subject>Sarcoma</subject><subject>Signal Transduction - drug effects</subject><subject>Silver - administration & dosage</subject><subject>Silver - pharmacokinetics</subject><subject>Silver - urine</subject><subject>Tissue Distribution</subject><subject>Tumors</subject><subject>Warburg Effect, Oncologic - drug effects</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Young Adult</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVUV1r3iAYldGxlne96Q8YQu8K6TRRk9wMSru2Y4WOtfdiokksiU-q5h3vv9pPnOkXnTzw-ODxnKMHoSNKTkvKydc4ODhlvOLVB3RAq6LKSsHI3rv9PjoM4YGkxUhe0_oT2i9yUXFC-QH6e-mXNkIwWQsqGo3PXB-ihwkHO26Nx9YNtrExYAjRQFC-hUnh3sOfOGDlNJ5MVCGVDXhrFZ7TXYjW9fj37V2mzWycNi5iNcOcdBIqDh6WfkjdYDVG41W04DB0uB-XNll5omxgtGHCze7VwUr56-LnZ_SxU2Mwhy99g-4vv9-fX2c3t1c_zs9uspYRETOqa22I4FQ1otM144asoyh0QQkXrC1F-g7CWcVYU5dMEMHKUnd5UYsVtkHfnmnnpZmMbtMTvBrl7O2k_E6CsvL_E2cH2cNWlgWvKaGJ4PiFwMPjYkKUD7B4lyzLnNdVnoRTQht08oxqPYTgTfemQIlc85VrvvIp3wT-8t7TG_Q1zeIfJAWlpg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Hu, Xiong-Ke</creator><creator>Rao, Shan-Shan</creator><creator>Tan, Yi-Juan</creator><creator>Yin, Hao</creator><creator>Luo, Ming-Jie</creator><creator>Wang, Zhen-Xing</creator><creator>Zhou, Jin-Hua</creator><creator>Hong, Chun-Gu</creator><creator>Luo, Zhong-Wei</creator><creator>Du, Wei</creator><creator>Wu, Ben</creator><creator>Yan, Zi-Qi</creator><creator>He, Ze-Hui</creator><creator>Liu, Zheng-Zhao</creator><creator>Cao, Jia</creator><creator>Wang, Yang</creator><creator>Situ, Wei-Yi</creator><creator>Liu, Hao-Ming</creator><creator>Huang, Jie</creator><creator>Wang, Yi-Yi</creator><creator>Xia, Kun</creator><creator>Qian, Yu-Xuan</creator><creator>Zhang, Yan</creator><creator>Yue, Tao</creator><creator>Liu, Yi-Wei</creator><creator>Zhang, Hong-Qi</creator><creator>Tang, Si-Yuan</creator><creator>Chen, Chun-Yuan</creator><creator>Xie, Hui</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><author>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Aqueous solutions</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Carbon</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Dehydrogenases</topic><topic>Efficiency</topic><topic>Female</topic><topic>Fructose - chemistry</topic><topic>Glucose</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Injections, Intravenous</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - secondary</topic><topic>Male</topic><topic>Metabolism</topic><topic>Metal Nanoparticles - administration & dosage</topic><topic>Metal Nanoparticles - chemistry</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - secondary</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Pancreatic cancer</topic><topic>Pharmacokinetics</topic><topic>Primary Cell Culture</topic><topic>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists & inhibitors</topic><topic>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Renal Elimination</topic><topic>Research Paper</topic><topic>Sarcoma</topic><topic>Signal Transduction - drug effects</topic><topic>Silver - administration & dosage</topic><topic>Silver - pharmacokinetics</topic><topic>Silver - urine</topic><topic>Tissue Distribution</topic><topic>Tumors</topic><topic>Warburg Effect, Oncologic - drug effects</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Xiong-Ke</creatorcontrib><creatorcontrib>Rao, Shan-Shan</creatorcontrib><creatorcontrib>Tan, Yi-Juan</creatorcontrib><creatorcontrib>Yin, Hao</creatorcontrib><creatorcontrib>Luo, Ming-Jie</creatorcontrib><creatorcontrib>Wang, Zhen-Xing</creatorcontrib><creatorcontrib>Zhou, Jin-Hua</creatorcontrib><creatorcontrib>Hong, Chun-Gu</creatorcontrib><creatorcontrib>Luo, Zhong-Wei</creatorcontrib><creatorcontrib>Du, Wei</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Yan, Zi-Qi</creatorcontrib><creatorcontrib>He, Ze-Hui</creatorcontrib><creatorcontrib>Liu, Zheng-Zhao</creatorcontrib><creatorcontrib>Cao, Jia</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Situ, Wei-Yi</creatorcontrib><creatorcontrib>Liu, Hao-Ming</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Yi-Yi</creatorcontrib><creatorcontrib>Xia, Kun</creatorcontrib><creatorcontrib>Qian, Yu-Xuan</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Yue, Tao</creatorcontrib><creatorcontrib>Liu, Yi-Wei</creatorcontrib><creatorcontrib>Zhang, Hong-Qi</creatorcontrib><creatorcontrib>Tang, Si-Yuan</creatorcontrib><creatorcontrib>Chen, Chun-Yuan</creatorcontrib><creatorcontrib>Xie, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Xiong-Ke</au><au>Rao, Shan-Shan</au><au>Tan, Yi-Juan</au><au>Yin, Hao</au><au>Luo, Ming-Jie</au><au>Wang, Zhen-Xing</au><au>Zhou, Jin-Hua</au><au>Hong, Chun-Gu</au><au>Luo, Zhong-Wei</au><au>Du, Wei</au><au>Wu, Ben</au><au>Yan, Zi-Qi</au><au>He, Ze-Hui</au><au>Liu, Zheng-Zhao</au><au>Cao, Jia</au><au>Wang, Yang</au><au>Situ, Wei-Yi</au><au>Liu, Hao-Ming</au><au>Huang, Jie</au><au>Wang, Yi-Yi</au><au>Xia, Kun</au><au>Qian, Yu-Xuan</au><au>Zhang, Yan</au><au>Yue, Tao</au><au>Liu, Yi-Wei</au><au>Zhang, Hong-Qi</au><au>Tang, Si-Yuan</au><au>Chen, Chun-Yuan</au><au>Xie, Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>10</volume><issue>17</issue><spage>7710</spage><epage>7729</epage><pages>7710-7729</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects.
A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays
were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis.
The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK).
Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>32685015</pmid><doi>10.7150/thno.45858</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1838-7640 |
ispartof | Theranostics, 2020-01, Vol.10 (17), p.7710-7729 |
issn | 1838-7640 1838-7640 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7359101 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Adolescent Animals Apoptosis Apoptosis - drug effects Aqueous solutions Bone cancer Bone Neoplasms - drug therapy Bone Neoplasms - pathology Cancer therapies Carbon Cell Line, Tumor Cell Proliferation - drug effects Chemotherapy Cisplatin - administration & dosage Dehydrogenases Efficiency Female Fructose - chemistry Glucose Humans Infant Infant, Newborn Injections, Intravenous Kinases Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - secondary Male Metabolism Metal Nanoparticles - administration & dosage Metal Nanoparticles - chemistry Metastasis Mice Mitochondria - drug effects Mitochondria - metabolism Osteosarcoma - drug therapy Osteosarcoma - secondary Oxidation-Reduction - drug effects Pancreatic cancer Pharmacokinetics Primary Cell Culture Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists & inhibitors Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism Reactive oxygen species Reactive Oxygen Species - metabolism Renal Elimination Research Paper Sarcoma Signal Transduction - drug effects Silver - administration & dosage Silver - pharmacokinetics Silver - urine Tissue Distribution Tumors Warburg Effect, Oncologic - drug effects Xenograft Model Antitumor Assays Young Adult |
title | Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A54%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fructose-coated%20Angstrom%20silver%20inhibits%20osteosarcoma%20growth%20and%20metastasis%20via%20promoting%20ROS-dependent%20apoptosis%20through%20the%20alteration%20of%20glucose%20metabolism%20by%20inhibiting%20PDK&rft.jtitle=Theranostics&rft.au=Hu,%20Xiong-Ke&rft.date=2020-01-01&rft.volume=10&rft.issue=17&rft.spage=7710&rft.epage=7729&rft.pages=7710-7729&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.45858&rft_dat=%3Cproquest_pubme%3E2598248418%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598248418&rft_id=info:pmid/32685015&rfr_iscdi=true |